GlassScriptPhysician profile
Daniel G Straka
NPI 1437388139
$2,410.22
in general payments reported to CMS, 2019-2025
24 companies · $65.44 in 2025
The $65.44 reported for 2025 was less than what a typical Ophthalmic Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $592 · 2020: $180 · 2021: $522 · 2022: $514 · 2023: $267 · 2024: $268 · 2025: $65.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $601.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $282.67 | 2019-2025 | |
| Abbvie INC. | $278.10 | 2022-2025 | Botox, Vuity, Lumigan |
| Aerie Pharmaceuticals, INC. | $276.51 | 2019-2021 | |
| Allergan, INC. | $266.55 | 2019-2022 | |
| Horizon Therapeutics Plc | $237.65 | 2019-2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $212.58 | 2019-2021 | |
| Revance Therapeutics, INC. | $125.66 | 2024 | Daxxify |
| Biotissue Holdings INC. | $104.65 | 2020-2023 | |
| Kala Pharmaceuticals, INC. | $100.18 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $86.13 | 2022-2023 | Acthar |
| Bausch & Lomb Americas INC. | $82.59 | 2022-2024 | Miebo, Vyzulta |
| Sun Pharmaceutical Industries INC. | $81.97 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $63.36 | 2019-2021 | |
| Alcon Vision LLC | $61.18 | 2021-2022 | |
| Rxsight INC | $19.60 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $17.67 | 2019 | |
| Merz North America, INC. | $17.38 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $17.28 | 2025 | |
| Merz Pharmaceuticals, LLC | $16.05 | 2023 | Xeomin |
| Kowa Pharmaceuticals America, INC. | $15.76 | 2023 | Seglentis |
| Mallinckrodt Enterprises LLC | $14.67 | 2019 | |
| Sight Sciences, INC. | $13.40 | 2019 | |
| Integra Lifesciences Corporation | $12.35 | 2021 | |
| Musculoskeletal Transplant Foundation INC. | $6.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Straka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.